| DB ID | MyCo_7235 |
| Title | Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWP-EBMT, EORTC-IDG and SEIFEM survey |
| Year | 2020 |
| PMID | 32009262 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | Haematology patients |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Europe |
| Cohort | None |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Recommendations on antifungal treatment duration have been established for most superficial and invasive yeast or dimorphic fungal infections. By contrast, although invasive aspergillosis (IA) is the third most frequent invasive fungal disease (IFD) optimal duration of antifungal (AF) treatment of invasive pulmonary aspergillosis (IPA) is not known, due to lack of evidence, and recommendations offer no practical guidance to clinicians on this topic. IDSA (Infectious Disease Society of America) guidelines state that duration of therapy for aspergillosis has not been optimally de- fined. In addition, European Society for Clinical Microbiology and Infectious Diseases (ESCMID), the European Confederation of Medical Mycology (ECMM) and the European Respiratory Society (ERS) guidelines state that treatment duration depends on clinical response and on immune reconstitution, that partial or complete remission requires no persistent clinical, or microbiological evidence of disease and that the range of the duration of treatment is huge. Close monitoring (eg non-enhanced computed tomography [CT] or biomarkers) is suggested once antifungal treatment is discontinued. |
| Technique | None |
| Analysis Method | None |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | None |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
